- Home
- AQMS vs ATHA Comparison
AQMS vs ATHA Comparison
Compare AQMS & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- ATHA
- Stock Information
- Founded
- AQMS 2014
- ATHA 2011
- Country
- AQMS United States
- ATHA United States
- Employees
- AQMS N/A
- ATHA N/A
- Industry
- AQMS Metal Fabrications
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- AQMS Industrials
- ATHA Health Care
- Exchange
- AQMS Nasdaq
- ATHA Nasdaq
- Market Cap
- AQMS 17.8M
- ATHA 21.0M
- IPO Year
- AQMS 2015
- ATHA 2020
- Fundamental
- Price
- AQMS $1.98
- ATHA $0.53
- Analyst Decision
- AQMS Strong Buy
- ATHA Buy
- Analyst Count
- AQMS 2
- ATHA 4
- Target Price
- AQMS $30.00
- ATHA $11.25
- AVG Volume (30 Days)
- AQMS 371.2K
- ATHA 235.4K
- Earning Date
- AQMS 11-14-2024
- ATHA 02-20-2025
- Dividend Yield
- AQMS N/A
- ATHA N/A
- EPS Growth
- AQMS N/A
- ATHA N/A
- EPS
- AQMS N/A
- ATHA N/A
- Revenue
- AQMS N/A
- ATHA N/A
- Revenue This Year
- AQMS N/A
- ATHA N/A
- Revenue Next Year
- AQMS N/A
- ATHA N/A
- P/E Ratio
- AQMS N/A
- ATHA N/A
- Revenue Growth
- AQMS 525.00
- ATHA N/A
- 52 Week Low
- AQMS $1.33
- ATHA $0.41
- 52 Week High
- AQMS $14.14
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- AQMS 41.02
- ATHA 41.88
- Support Level
- AQMS $1.92
- ATHA $0.52
- Resistance Level
- AQMS $2.14
- ATHA $0.57
- Average True Range (ATR)
- AQMS 0.28
- ATHA 0.04
- MACD
- AQMS -0.05
- ATHA -0.00
- Stochastic Oscillator
- AQMS 6.32
- ATHA 11.82
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.